Szerző:
Constantine S. Tam, MBBS, MD1
Tanya Siddiqi, MD2
John N. Allan, MD3
Thomas J. Kipps, MD, PhD4
Ian W. Flinn, MD, PhD5
Bryone J. Kuss, MBBS, PhD, FRACP, FRCPA6
Stephen Opat, FRACP, FRCPA, MBBS7
Paul M. Barr, MD8
Alessandra Tedeschi, MD9
Ryan Jacobs, MD10
Xavier C. Badoux, MBBS, FRACP, FRCPA11
Paolo Ghia, MD, PhD12
Juthamas Sukbuntherng, PhD13
Ahmed Hamed Salem, PhD, FCP14
Kristin Russell, BS15
Karl Eckert, BA16
Cathy Zhou, MS17
Joi Ninomoto, PharmD18
Danelle F. James, MD, MAS19
William G. Wierda, MD, PhD20
1St. Vincent's Hospital and University of Melbourne, Peter MacCallum Cancer Centre, Melbourne, Australia
2City of Hope National Medical Center, Duarte, CA
3Weill Cornell Medicine, Long Island City, NY
4UCSD Moores Cancer Center, San Diego, CA
5Sarah Cannon Research Institute/Tennessee Oncology, Nashville, TN
6Flinders Medical Centre, Bedford Park, Australia
7Monash University, Clayton, VIC, Australia
8Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY
9ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy
10Department of Hematology, Lymphoma Division, Levine Cancer Institute, Charlotte, NC
11Ministry of Health, St George Hospital, Kogarah, Australia
12Università Vita-Salute San Raffaele and IRCCS Ospedale San Raffaele, Milan, Italy
13Pharmacyclics LLC, an AbbVie Company, Sunnyvale, CA
14AbbVie, North Chicago, IL
15Pharmacyclics LLC, an AbbVie Company, Sunnyvale, CA
16Pharmacyclics LLC, an AbbVie Company, Sunnyvale, CA
17Pharmacyclics LLC, an AbbVie Company, Sunnyvale, CA
18Pharmacyclics LLC, an AbbVie Company, Sunnyvale, CA
19Pharmacyclics LLC, an AbbVie Company, Sunnyvale, CA
20University of Texas M.D. Anderson Cancer Center, Houston, TX
Background: Ibr is the only once-daily inhibitor of Bruton tyrosine kinase with significant overall survival benefit demonstrated in 2 randomized phase 3 studies in first-line CLL (RESONATE-2; ECOG1912). Both Ibr and Ven, an oral inhibitor of BCL2, are approved in the US for treatment of CLL/SLL. The combination of Ibr + Ven may have synergistic anti-tumor activity given the capacity of Ibr to mobilize CLL cells from protected niches within ...